Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PIGY divergent transcript (PIGY-DT) is a noncoding RNA transcribed from a region adjacent to the PIGY gene on chromosome 4q22.1. It belongs to a class of divergent transcripts, a phenomenon where both sides of a promoter are transcribed in opposite directions, usually producing RNA molecules that do not code for proteins. Most divergent transcripts are unstable and have unknown or minimal cellular functions. While divergent transcription is hypothesized to contribute to gene origination and genomic evolution, PIGY-DT itself is not associated with any established protein-coding function or disease relevance, nor is it recognized as a drug target or biomarker[1][2].
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PIGY divergent transcript (PIGY-DT).